Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
McKesson
Colorcon
Boehringer Ingelheim
Express Scripts

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Mapracorat

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Mapracorat: Sponsors, patents, clinical trial progress

Mapracorat is an investigational drug.

There have been 12 clinical trials for Mapracorat. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2011.

The most common disease conditions in clinical trials are Inflammation, Cataract, and Eczema. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].

There are three US patents protecting this investigational drug and fifty-seven international patents.

Recent Clinical Trials for Mapracorat
TitleSponsorPhase
1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to MapracoratBayerPhase 1
Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 DaysBausch & Lomb IncorporatedPhase 1
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryBausch & Lomb IncorporatedPhase 3

See all Mapracorat clinical trials

Clinical Trial Summary for Mapracorat

Top disease conditions for Mapracorat
Top clinical trial sponsors for Mapracorat

See all Mapracorat clinical trials

US Patents for Mapracorat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mapracorat   Start Trial 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents Schering AG (Berlin, DE)   Start Trial
Mapracorat   Start Trial Pharmaceutical composition for topical application of poorly soluble compounds Intendis GmbH (Berlin, DE)   Start Trial
Mapracorat   Start Trial Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma Northwestern University (Evanston, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Mapracorat

Drugname Country Document Number Estimated Expiration Related US Patent
Mapracorat Argentina 051767 2024-11-12   Start Trial
Mapracorat Australia 2005303926 2024-11-12   Start Trial
Mapracorat Brazil PI0517797 2024-11-12   Start Trial
Mapracorat Canada 2586689 2024-11-12   Start Trial
Mapracorat China 101124220 2024-11-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.